Pegfilgrastim

Common brands: Neulasta, Fylnetra, Cyclophosphamide, Frindovyx, Doxorubicin Hydrochloride

Top reporter: Amgen, Inc

Leukocyte Growth Factor [EPC]Alkylating Drug [EPC]Corticosteroid [EPC]Platinum-based Drug [EPC]Microtubule Inhibitor [EPC]
97,462
Total Reports
33,650
Serious Reports
5,224
Death Reports
30
Reported Reactions
Death Report Ratio: High (5.36%)

Patient Demographics

Male
27,246
Female
52,435

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Pegfilgrastim.

# Reaction Reports % of Total
1 DEVICE ADHESION ISSUE 11,595
11.2%
2 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 10,244
9.9%
3 UNINTENTIONAL MEDICAL DEVICE REMOVAL 8,985
8.7%
4 DEVICE MALFUNCTION 6,868
6.7%
5 DEVICE USE ERROR 6,041
5.9%
6 DEVICE ISSUE 5,128
5.0%
7 ACCIDENTAL EXPOSURE TO PRODUCT 4,990
4.8%
8 OFF LABEL USE 3,777
3.7%
9 FEBRILE NEUTROPENIA 3,740
3.6%
10 DEVICE OCCLUSION 3,307
3.2%
11 BONE PAIN 2,942
2.9%
12 DEATH 2,767
2.7%
13 NEUTROPENIA 2,635
2.6%
14 FATIGUE 2,610
2.5%
15 PYREXIA 2,493
2.4%
16 NAUSEA 2,454
2.4%
17 DRUG DOSE OMISSION 2,104
2.0%
18 DRUG DOSE OMISSION BY DEVICE 2,098
2.0%
19 DIARRHOEA 1,968
1.9%
20 PAIN 1,759
1.7%
21 ALOPECIA 1,735
1.7%
22 DYSPNOEA 1,620
1.6%
23 INTERCEPTED PRODUCT PREPARATION ERROR 1,572
1.5%
24 VOMITING 1,420
1.4%
25 ANAEMIA 1,416
1.4%
26 OCCUPATIONAL EXPOSURE TO PRODUCT 1,412
1.4%
27 APPLICATION SITE HAEMORRHAGE 1,397
1.4%
28 DEVICE LEAKAGE 1,387
1.3%
29 DEVICE PHYSICAL PROPERTY ISSUE 1,381
1.3%
30 APPLICATION SITE PAIN 1,264
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.